Expert Review Of ImClone Protocol Concludes C225 Approval Unlikely.
Retrospective Data Clean-Up Can’t Help C225 Phase II Trial; Protocol Far Too “Fuzzy”.
ImClone Protocol Generates More Questions Than Answers.
Phase III Trial Would Give Clearer Picture Of C225 Role.
Thomas Jordan To Help ASCO Enhance International Relations, Retires From BMS.
Levine Leaves Presidency Of Rockefeller University.
Trending Stories
- As his Senate testimony alleged danger from mRNA COVID vaccine, El-Deiry had an offer to run NCI Frederick lab
The job offer to run the lab—home to virus research, RAS Initiative, and data science—was quickly rescinded - Proposed OMB rule aims at the heart of the U.S. research enterprise—and scientists are fighting back
“The question isn’t whether politics will influence research. Under this proposal, that’s the point. That’s their goal.” - Peter F. Garrett to people with cancer: Your story has power
- Lessons from the AIDS Quilt: what the cancer world can learn from AIDS advocacy
- Survivorship begins at diagnosis—cancer care system must recognize this
- House bill gives NCI $7.4 billion in FY 2027—$110 million above current budget









